echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Lancet Neurology: Early-8 protein-1 E280A normal chromosomal explicit Alzheimer's family plasma nerve wire light chain: a cross-sectional and longitudinal cohort study

    Lancet Neurology: Early-8 protein-1 E280A normal chromosomal explicit Alzheimer's family plasma nerve wire light chain: a cross-sectional and longitudinal cohort study

    • Last Update: 2020-12-11
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Early-on-age protein-1 is a large molecular protein on endocytoplasms and goerki bodies, consisting of 467 amino acid residues.
    studies have shown that it is associated with Alzheimer's disease.
    nerve wire light chain (NfL) is an important part of the large-caliber myelin dextide cytostic skeleton, and is a promising biomarker in axon damage and neuron degenerative change.
    NfL concentrations in cerebrospinal fluid, serum and plasma have been used to detect and track neurodegeneration in individuals with Alzheimer's disease and other neurodegenerative diseases, neuroinfeditation, trauma and cerebrovascular disease.
    In this study, the authors' team used available cross-sectional plasma samples to show NfL concentrations in participants at the Alzheimer's Prevention Initiative Registry in Colombia, including age-matched early-onset protein-1 (PSEN1) E280A mutation carriers and non-carriers.
    , vertical plasma samples from carriers and non-carriers with an average follow-up of 6 years were analyzed to determine changes in plasma NfL.
    baseline assessment was conducted on 1,070 PSEN1 E280A mutation carriers and 1,074 non-carriers, of which 242 mutant carriers and 262 non-carriers were measured vertically (on average, 6 years of follow-up).
    Plasma NfL measurements increased with age in both groups (p .lt; 0 0001) and began to distinguish carriers and non-carriers at age 22 (22 years ahead of the estimated meso aged 44 for mild cognitive impairment), although plasma NfL's ability to distinguish carriers from non-carriers reached a high sensitivity only when approaching the clinical age of onset.
    In summary, plasma and serum NfL measurements are useful in detecting neurodegenerative degeneration and axon damage, starting with a slight increase long before the onset of clinical symptoms of Alzheimer's disease, while larger, more sensitive elevations are closer to impending clinical damage.
    this study provides the basis for further exploration of blood-based NfL measurements to provide information for prognosis and to evaluate treatments aimed at preventing Alzheimer's disease and related diseases, some of which are associated with elevated NfL.
    Quiroz, Yakeel T et al. Plasma neurofilament light chain in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional and longitudinal cohort study. The Lancet Neurology, Volume 19, Issue 6, 513 - 521MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to reproduce by any media, website or individual.
    all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
    at the same time reproduced content does not represent the position of this site.
    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.